An experimental drug has restored memory and learning in mice that were already showing severe signs of Alzheimer\u2019s disease.<\/p>\n\n\n\n
By bringing a crucial energy molecule in brain cells back to healthy levels, the treatment suggests that even advanced mental decline may not be permanent.<\/p>\n\n\n\n
In tests that measure recognition and navigation, treated mice performed like healthy animals again after symptoms had set in.<\/p>\n\n\n\n\n\n
Using those readouts, Andrew A. Pieper, M.D., Ph.D., at Case Western Reserve University (CWRU<\/a>) traced the recovery to restored brain chemistry.<\/p>\n\n\n\n Pieper watched late-stage animals regain cognitive skills, a result that challenges the belief that advanced decline only moves one way.<\/p>\n\n\n\n That reversal made the team look for a shared weakness inside stressed neurons, rather than chasing each symptom separately.<\/p>\n\n\n\n Inside neurons, the team focused on NAD+<\/a>, a helper molecule that moves energy, and it often drops with age.<\/p>\n\n\n\n The experimental drug helped the brain keep that molecule in a normal range, instead of letting it crash during disease.<\/p>\n\n\n\n\n\n After six months of daily injections, NAD+ levels returned to normal in mice that already showed advanced symptoms.<\/p>\n\n\n\n Keeping that fuel supply steady also lowered signs of cell stress, suggesting that energy balance can steady many systems at once.<\/p>\n\n\n\n Autopsies often reveal plaques and tangles in Alzheimer’s disease<\/a>, and the mouse brains carried similar buildups.<\/p>\n\n\n\n In one model, amyloid-beta, a protein fragment that clumps between neurons, stayed abundant even as behavior improved on memory tasks.<\/p>\n\n\n\n Across the tau-based model, tau, a nerve-cell protein that can twist into tangles, also changed form while cognition recovered.<\/p>\n\n\n\n That outcome left a hard message, neurons can regain function even when classic protein debris remains in the background.<\/p>\n\n\n\n Leakiness in the blood-brain barrier<\/a>, the filter that controls brain entry, eased after the experimental drug restored vessel linings.<\/p>\n\n\n\n Microscope images showed tighter seals and less immune leakage, changes that can cut inflammation inside delicate brain tissue.<\/p>\n\n\n\n\n\n When human endothelial cells, cells that line tiny brain vessels, faced oxidative damage in dishes, the experimental drug protected them.<\/p>\n\n\n\n Stronger vessel walls may have helped the drug reach neurons safely, while also limiting outside signals that worsen symptoms.<\/p>\n\n\n\n Markers of neuroinflammation, immune activity that irritates brain cells, dropped after treatment in the mice with advanced symptoms.<\/p>\n\n\n\n Activated support cells quieted, and the data linked that change to steadier NAD+ that left fewer distress signals.<\/p>\n\n\n\n Levels tied to oxidative stress, chemical wear that damages fats and proteins, also fell after months of dosing.<\/p>\n\n\n\n Reducing those stressors mattered because they can scramble synapses, the connections that let brain circuits store memories.<\/p>\n\n\n\n Human brain samples showed about a 30% drop in NAD+ compared with controls, matching worse damage across many measures.<\/p>\n\n\n\n In those tissues, lower NAD+ lined up with more tau injury, more oxidative damage, and weaker blood vessel protections.<\/p>\n\n\n\n A summary captured Pieper’s view that restoring brain energy can support recovery, even when symptoms look entrenched.<\/p>\n\n\n\n “The damaged brain can, under some conditions, repair itself and regain function,” says Pieper.<\/p>\n\n\n\nAn energy reset<\/h2>\n\n\n\n
Plaques were not fate<\/h2>\n\n\n\n
Barrier walls recovered<\/h2>\n\n\n\n
Inflammation calmed down<\/h2>\n\n\n\n
Human brains matched<\/h2>\n\n\n\n
Cancer risk matters<\/h2>\n\n\n\n